title: Rapid delivery of small interfering RNA by biosurfactant MEL-A-containing liposomes.
abstract: The downregulation of gene expression by RNA interference holds great potential for genetic analysis and gene therapy. However, a more efficient delivery system for small interfering RNA (siRNA) into the target cells is required for wide fields such as cell biology, physiology, and clinical application. Non-viral vectors are stronger candidates than viral vectors because they are safer and easier to prepare. We have previously used a new method for gene transfection by combining cationic liposomes with the biosurfactant mannosylerythritol lipid-A (MEL-A). The novel MEL-A-containing cationic liposomes rapidly delivered DNA (plasmids and oligonucleotides) into the cytosol and nucleus through membrane fusion between liposomes and the plasma membrane, and consequently, enhanced the gene transfection efficiency. In this study, we determined the efficiency of MEL-A-containing cationic liposomes for siRNA delivery. We observed that exogenous and endogenous protein expression was suppressed by approximately 60% at 24h after brief (30 min) incubation of target cells with MEL-A-containing cationic liposome/siRNA complexes. Confocal microscopic analysis showed that suppression of protein expression was caused by rapid siRNA delivery into the cytosol. We found that the MEL-A-containing cationic liposomes directly delivered siRNA into the cytoplasm by the membrane fusion in addition to endocytotic pathway whereas Lipofectamine RNAiMax delivered siRNA only by the endocytotic pathway. It seems that the ability to rapidly and directly deliver siRNA into the cytosol using MEL-A-containing cationic liposomes is able to reduce immune responses, cytotoxicity, and other side effects caused by viral vectors in clinical applications.
authors: School of Pharmacy, Aichi Gakuin University, 1-100 Kusumoto-cho, Chikusa-ku, Nagoya 464-8650, Japan.
authors: Yoshikazu
authors: Y
authors: Inoh
authors: Tadahide
authors: T
authors: Furuno
authors: Naohide
authors: N
authors: Hirashima
authors: Dai
authors: D
authors: Kitamoto
authors: Mamoru
authors: M
authors: Nakanishi
mesh_terms: D000818:Animals; D003593:Cytoplasm / Q000378:metabolism*; D015316:Genetic Therapy / Q000379:methods; D006017:Glycolipids / Q000737:chemistry; D008050:Lipid A / Q000737:chemistry; D008081:Liposomes; D008546:Melanoma, Experimental; D008561:Membrane Fusion; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D034622:RNA Interference; D034741:RNA, Small Interfering / Q000008:administration & dosage* / Q000235:genetics / Q000378:metabolism; D013501:Surface-Active Agents / Q000737:chemistry*; D014162:Transfection / Q000379:methods*
chemical_list: D006017:Glycolipids; D008050:Lipid A; D008081:Liposomes; D019253:Proto-Oncogene Proteins c-bcl-2; D034741:RNA, Small Interfering; D013501:Surface-Active Agents; C439671:mannosylerythritol lipid